{"entity":{"id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","aka":[],"tldr":"A phase 3 trial of Tisagenlecleucel, Lenalidomide, Rituximab in follicular lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma is a phase 3 interventional study registered as NCT05888493 by Novartis Pharmaceuticals, with 109 participants enrolled, started 2023-10-02 and due to reach its primary completion in 2028-07-25. Interventions recorded: Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles, Lymphodepleting chemotherapy, Corticosteroids and/or Radiation (Bridging therapy). Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05888493","url":"https://clinicaltrials.gov/study/NCT05888493"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tisagenlecleucel","lenalidomide","rituximab","cyclophosphamide","doxorubicin","vincristine"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05888493","phase":"3","setting":"A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL)","sponsor":"Novartis Pharmaceuticals","enrolled":109,"outcomes":[]},"route":"/trials/nct05888493/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}